Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2008

View Archived Issues

Sanofi-aventis reports Q2 highlights

Santhera provides update on idebenone for the treatment of Friedreich's ataxia

KUR-212 follow-up results of phase IIa trial in patients with burns requiring mesh grafting

Enrollment in phase IIb clinical trial for I-vation TA (MK-0140) suspended

New delta opioid receptor antagonist with antitussive activity identified at Toray

Bioavailability similar with ritonavir tablet and capsule formulations

Study shows long-term efficacy of tipranavir-ritonavir treatment for children with AIDS

CASTLE data on atenovir/ritonavir, lopinavir/ritonavir analyzed by gender, race and renal effects

AstraZeneca: Q2 regulatory and development update

Aloe extract UP-780 upregulates adiponectin expression, reduces HbA1c

Novel antiviral, antibacterial agents disclosed in recent patents

New compounds for treatment of inflammation revealed in patent literature

Recent patents disclose new anticancer compounds

NeuroSearch reports positive results from TIPO-2 human metabolic study of tesofensine

FDA grants marketing approval to Gilead's Viread for chronic hepatitis B

FDA issues approvable letter for NDA for Kynapid in atrial fibrillation

Oncolytics completes dose escalation in REO 010 clinical trial of Reolysin and docetaxel

Enrollment completed in phase IIa study of brostallicin in soft tissue carcinoma

Fresenius Kabi completes acquisition of Dabur Pharma

Preclinical data on memogain, a galantamine prodrug, reported by Galantos

ErbB3 antagonist MM-121 begins phase I trial

Phase III study of Trizytek meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...